Trial success, then a capital raise

Ondine Biomedical (LSE:OBI) is raising new share capital after its US Phase 3 trial produced positive results. On 30 September 2026, the company published its interim results and said it planned a share raise, including a retail offer, through AIM's new Capital Access Window. Trading in its shares was voluntarily paused from 7:30am that day and will stay paused until the fundraise results are announced. The company says the pause is meant to reach a wider range of investors and support pricing stability.

What the company does

Ondine is a Canadian life sciences group listed on AIM. It develops light-activated antimicrobial therapies. Its lead product, Steriwave, is a nasal photodisinfection treatment designed to reduce hospital infections, including surgical site infections. Steriwave is authorised in Canada, the UK and certain other markets. In the United States it is limited to investigational use and has not been approved by the FDA.

Latest developments

On 1 September, Ondine reported positive topline results from LANTERN, its pivotal US Phase 3 study. The trial enrolled 5,188 patients and met its primary efficacy endpoint, showing a 40.5% relative reduction in the risk of 30-day surgical site infection. The posterior probability of benefit was 98.2%. The topline review found no treatment-related serious adverse events, and the full analysis is still under way. The company is targeting a pre-NDA meeting with the FDA in the first quarter of 2027 and an NDA submission in mid-2027. Both targets depend on funding and on finishing the analysis.

Commercial adoption has also continued. The company announced that the NHS Golden Jubilee in Scotland had adopted Steriwave and that Hospital Ángeles in Mexico was running a multi-centre pilot. Steriwave is also expanding across hospitals in Ontario. In June, a Leeds study in complex brain surgery reported a 78% reduction in surgical site infections compared with mupirocin. Ondine is also working with Mela Solutions on an evaluation in NHS intensive care units.

Financial picture

First-half revenue rose 23% to C$1.25 million, helped by higher use at existing accounts and new deployments. The net loss widened to C$16.2 million from C$12.6 million, mainly because of spending on the LANTERN trial. Cash fell to C$5.3 million at 30 June from C$10.6 million at the end of 2025. Ondine said its cash would fund operations into mid-Q4 2026, which is why it began the new raise. It plans to use the proceeds for publishing the full trial analyses, FDA preparation, commercial pilots, sales and marketing, and working capital. The company does not pay a dividend.

Sector and index context

Ondine is one of a number of clinical-stage healthcare companies measured against the FTSE AIM All Share Index. Companies at this stage often see their shares re-rate sharply around trial readouts, while funding needs can weigh on valuations. Hospital-acquired infections remain a costly problem for health systems, which supports interest in non-antibiotic approaches.

Key risks

The immediate risk is funding, because cash runway is short and the terms of the raise are not yet known. A large raise could significantly dilute existing shareholders. Regulatory risk remains, since topline data do not guarantee FDA approval. Turning pilots into steady revenue across several health systems may also take time.

What to watch next

The key near-term event is the outcome of the Capital Access Window raise, including its price and size, and the resumption of trading. After that, investors will look for publication of the full LANTERN analyses, preparation for the pre-NDA meeting, planned changes to the board and senior management, and further hospital contracts in Canada, the UK and Mexico.